[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586191":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":40,"locations":46,"responsibleParty":64,"collaborators":11,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Zhejiang Wenda Pharma Technology LTD.","OTHER",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: WD-890 Dose 1 QD and Placebo","EXPERIMENTAL",null,[13],"Drug: WD-890 tablet",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2: WD-890 Dose 2 QD and Placebo",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Group 3: WD-890 Dose 3 QD and Placebo",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Group 4: Placebo",[23],"Drug: Placebo",[25,30,33,36],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","WD-890 tablet","Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[9],{"type":26,"name":27,"description":31,"armGroupLabels":32,"otherNames":11},"Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[15],{"type":26,"name":27,"description":34,"armGroupLabels":35,"otherNames":11},"Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.",[18],{"type":26,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Placebo","Participants will receive placebo QD from Week 0 through Week 16.",[21],[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Qianjin Lu, doctor","CONTACT","+86 137 8709 7676","qianlu5860@pumcderm.cams.cn",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":56,"coordinates":57},"Point",[58,59],118.77778,32.06167,{"lat":59,"lon":58},[62],{"name":42,"role":43,"phone":63,"phoneExt":11,"email":45},"+86 13787097676",{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100586191","phase-2-a-study-of-wd-890-in-participants-with-moderate-to-severe-plaque-psoriasis-100586191",false,"NCT06912165","A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n\n  ≥10% of BSA involvement at screening visit and randomization;\n* Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria\n* Participant with a history of chronic bacterial infections (e.g., chronic pyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).","ALL","18 Years","70 Years",{"count":77,"type":78},140,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.",[84],"Brief Description of Focus of Study","2025-04-08",{"date":87,"type":88},"2025-04-11","ACTUAL",{"date":90,"type":88},"2024-12-31",{"date":92,"type":78},"2025-11-30",{"name":5,"class":6},1]